For Ewing sarcoma (ES), BCL-2 and BCL-XL are simultaneously required to maintain cell survival, and monotherapy with venetoclax is not sufficient to sensitize ES cells to olaparib. Here, BCL2L1 is linked to Ewing sarcoma.